Allos Therapeutics has signed a co-development and commercialisation agreement with Mundipharma, potentially worth US$360 M, for its peripheral T-cell lymphoma (PTCL) drug, Folotyn® (pralatrexate injection). Allos will retain commercialisation rights in the US and Canada, while Mundipharma will gain exclusive rights to commercialise Folotyn in the rest of the world. Folotyn is the first drug to have gained US FDA approval for relapsed or refractory PTCL but its sales have been slower than expected.